The Developmental Therapeutics Program (DTP) operates a progressive, tiered in vitro and in vivo anti-cancer compound screening program for single pure compounds with the goal of identifying and evaluating novel chemical leads and biological mechanisms of action. The program does not support screening of chemical libraries. The DTP screens include the NCI 60 cell line screen and, as appropriate, the hollow fiber assay and relevant human tumor xenograft and rodent tumor models. Information on the experimental details for the screens, the overall DTP testing paradigm, instructions on submitting compounds and the execution of confidentiality agreements with NCI can be found at the links below.
The following document is in Adobe PDF format.
- This printable chart (pdf) summarizes the DTP anti-cancer compound screening services decision tree along with a color-coded key indicating the communication method, between DTP and suppliers, for decisions and data transfer.
- Instructions for submission of purified natural products and synthetic compounds for tumor cell line screening.